Orca-T Improved Survival in Blood Cancer Patients
A study showed better long-term outcomes for patients receiving Orca-T compared to standard PTCy-based prophylaxis.
Updated on Sept. 22, 2026 in Cancer

Live Poll
Do you trust that new medical cell therapies offer better long-term survival than traditional treatments?
Patients receiving Orca-T for hematologic malignancies achieved an 83% 3-year overall survival rate, significantly outperforming the 66% rate seen in the PTCy cohort. The study, involving myeloablative HSCT, reported superior survival metrics across one, two, and three-year benchmarks.
Why it matters
These results indicate that Orca-T provides a more effective clinical alternative to traditional PTCy methods for improving long-term outcomes. The data highlights a substantial reduction in nonrelapse mortality, offering a potential shift in transplant standard-of-care protocols.
Orca-T patients demonstrated a 3.1% nonrelapse mortality rate compared to 10% in the PTCy group. Additionally, Orca-T users achieved a 71% 3-year relapse-free survival rate, significantly higher than the 57% observed in the PTCy cohort.
The players
UCLA
This university research center served as a site for transplant research and clinical analysis.
The details
Researchers observed a median of 12 days for neutrophil engraftment among Orca-T patients, with no instances of primary graft failure reported during the study. Participants across both groups received myeloablative conditioning and grafts from 8/8 HLA-matched donors.
Timeline
June 2026: Orca-T received FDA approval for matched-donor myeloablative HSCT.
The Orca-T cohort had a median follow-up of 42 months, while the PTCy group had a median follow-up of 33 months.
The Big Picture
This study advances the clinical outcomes of myeloablative HSCT, marking a departure from previous standard-of-care reliance on PTCy prophylaxis.
Patients and healthcare providers now have an FDA-approved alternative that demonstrates lower nonrelapse mortality and faster engraftment times. This development provides a tangible improvement in recovery expectations for those requiring myeloablative HSCT treatment.
The takeaway
The study confirms that Orca-T significantly enhances survival probabilities for patients undergoing stem cell transplants for blood cancers. Clinicians may increasingly prioritize this therapy to reduce post-transplant risks and improve long-term relapse-free rates.
Further reading
For more on evolving treatment standards, visit the Cancer section.
Source note: This article includes information reported by OncLive.
Live Poll
Do you trust that new medical cell therapies offer better long-term survival than traditional treatments?






